Evidence map›Paper›PMID 38727881›Full record

ArticleMolecular biotechnology2025

PCDHGA10 as a Potential Biomarker of Lung Squamous Cell Carcinoma Based on Bioinformatics and Experimental Verification.

Shuming Song, Ruijiao Lu, Yuanya Chen, Yangchun Feng

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Shuming Song *Xinjiang Key Laboratory of Oncology, Cancer Hospial Affiliated to Xinjiang Medical University, Urumqi, China.
Ruijiao Lu *Clinical Laboratory Center, Cancer Hospial Affiliated to Xinjiang Medical University, Urumqi, China.
Yuanya ChenGeneral Surgery Department, People's Hospital of Bachu County, Xinjiang, Kashgar, China.
Yangchun FengClinical Laboratory Center, Cancer Hospial Affiliated to Xinjiang Medical University, Urumqi, China. paopao1987123@163.com.ORCID http://orcid.org/0009-0006-6194-1949

Funding

Natural Science Foundation of Xinjiang Uygur Autonomous Region 2022D01C303
6 · The paper itself

Abstract

Procalcitonin gamma subfamily A, 10 (PCDHGA10) is a member of the procalcitonin gamma gene cluster, which is associated with neuronal synapse development. However, there are lack of studies on the role and potential prognostic value of PCDHGA10 in lung squamous cell carcinoma (LUSC). We analyzed the RNAseq data of PCDHGA10 to compare their expression differences. Then survival analysis, tumor microenvironment (TME) analysis, and mutation analysis were carried out. Additionally, we performed gene ontology (GO) and kyoto gene encyclopedia (KEGG) enrichment analyses to explore potential signal pathways. PCDHGA10 protein expression was evaluated using immunohistochemistry (IHC) on tissue microarrays (HLugS180Su02). By microarray analysis and database analysis, we found that PCDHGA10 was significantly highly expressed in LUSC. Sufferers with elevated PCDHGA10 levels exhibited a worse prognosis, according to the survival analysis. The PCDHGA10 mutation was also linked to LUSC patient prognosis. Besides, PCDHGA10 was closely related to tumor immune cell infiltration and immune checkpoints. In conclusion, PCDHGA10 is expected to become a new molecular marker for LUSC.

Indexed as

Biomarkers, TumorCadherinsCarcinoma, Squamous CellLung NeoplasmsComputational BiologyFemaleGene Expression Regulation, NeoplasticHumansMaleMutationPrognosisProtocadherinsSurvival AnalysisTumor MicroenvironmentBiomarkers, TumorCadherinsProtocadherinsExpressionLung squamous cell carcinomaPCDHGA10PrognosisTumor microenvironment

Identifiers

PMID38727881

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.